Compare Adaptive Biotechnologies Corp (ADPT) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Home Depot Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.98 (market cap $4.05B), while Home Depot Inc trades at $354.5 (market cap $349.77B). The key difference: Home Depot Inc is far larger — about 86.4× Adaptive Biotechnologies Corp's market cap, and Home Depot Inc pays a 2.66% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HD | |
|---|---|---|
Market Cap | $4.05B | $349.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $423.42 |
52-Week Low | $12.30 | $297.51 |
Enterprise Value | $4.12B | $411.32B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in 2025 revenue with solid profitability metrics including 8.41% net income margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations set at $4.73 EPS. The stock faces headwinds from weakening big-ticket demand and rising mortgage rates, but maintains strong analyst support with 59% buy ratings.
Home Depot presents a compelling long-term investment case with stable fundamentals and professional segment growth potential, though near-term challenges include housing market sensitivity and margin pressure. The consensus price target of $368.75 suggests 5.1% upside potential from current levels, supported by strong cash flow generation and dividend payments. Key risks include consumer spending volatility and competitive pressures in the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
